Holen Sie sich die Stockscreener-App
1.15
13.86%
0.14
Handel nachbörslich:
1.10
-0.05
-4.35%
Schlusskurs vom Vortag:
$1.01
Offen:
$1.05
24-Stunden-Volumen:
857.22K
Relative Volume:
0.24
Marktkapitalisierung:
$12.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.95M
KGV:
-0.5139
EPS:
-2.2377
Netto-Cashflow:
$-7.28M
1W Leistung:
+9.52%
1M Leistung:
+24.32%
6M Leistung:
-44.17%
1J Leistung:
-12.88%
1-Tages-Spanne:
$1.04
$1.15
1-Wochen-Bereich:
$0.978
$1.16
52-Wochen-Spanne:
$0.8127
$4.1899
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Firmenname
Phio Pharmaceuticals Corp
Sektor
Branche
Telefon
(508) 767-3861
Adresse
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.15 | 10.87M | 0 | -7.95M | -7.28M | -2.2377 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-05 | Eingeleitet | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Aktie (PHIO) Neueste Nachrichten
PHIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients - Sahm
PHIO Should I Buy - Intellectia AI
PHIO Technical Analysis & Stock Price Forecast - Intellectia AI
Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company - Weekly Voice
Phio Pharmaceuticals Reports Promising Phase 1b Results for Skin Cancer Therapy, Plans FDA Submission for 2026 - citybuzz -
Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894 - The Courier-Journal
Is Phio Pharmaceuticals Corp. stock trending bullish2025 Major Catalysts & Advanced Technical Analysis Signals - mfd.ru
Phio Pharmaceuticals Boosts CEO Severance and Incentive Compensation - TipRanks
Phio reshapes leadership as PH-762 cancer drug nears key tests - Stock Titan
CEO contract changes at Phio (NASDAQ: PHIO) lift bonus target - Stock Titan
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
CVI and Heights disclose 9.9% Phio (PHIO) stake based on warrant holdings - Stock Titan
Will Phio Pharmaceuticals Corp. benefit from rising consumer demandWeekly Investment Report & Advanced Swing Trade Entry Alerts - mfd.ru
What are Phio Pharmaceuticals Corp.’s growth leversInsider Buying & AI Forecast for Swing Trade Picks - mfd.ru
DealFlow Discovery Conference: Opportunities Unveiled - timothysykes.com
Can Phio Pharmaceuticals Corp. lead its sector in growthEarnings Growth Summary & Growth Focused Stock Reports - mfd.ru
Phio Pharmaceuticals Corp. (PHIO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PHIO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Aug Closing: Is Phio Pharmaceuticals Corp. being accumulated by smart moneyJuly 2025 Reactions & Real-Time Chart Breakout Alerts - mfd.ru
What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday? - Benzinga
Best Penny Stocks To Watch Now – February 10th - Defense World
DealFlow Events Sets Stage for PEIO Stock Momentum - StocksToTrade
Phio reports positive results from PH-762 skin cancer trial By Investing.com - Investing.com Australia
Phio Pharmaceuticals (PHIO) stock rises premarket as new PH-762 skin cancer data keeps traders circling - TechStock²
Phio reports positive results from PH-762 skin cancer trial - Investing.com South Africa
PHIO: HC Wainwright & Co. Reiterates Buy Rating with $14 Price T - GuruFocus
Phio Pharmaceuticals Corp. (PHIO) stock: jumps 43% as cancer trial shows strong safety and response rates - parameter.io
DealFlow Conference Set to Boost Over 100 Companies - StocksToTrade
Phio Pharmaceuticals stock soars after strong cancer treatment results - Investing.com
Phio Pharmaceuticals stock soars after strong cancer treatment results By Investing.com - Investing.com Nigeria
DealFlow Discovery Conference Unveils Corporate Opportunities - timothysykes.com
Phio Pharmaceuticals Reports Positive PH-762 Phase 1b Safety Results - TipRanks
Phio Pharmaceuticals Corp Announces Positive Phase 1b Trial Results for PH-762 - TradingView
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Top PH-762 skin cancer dose triggers 85% tumor response in Phio trial - Stock Titan
Retail Surge: Does Phio Pharmaceuticals Corp offer margin of safety2025 Growth vs Value & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Can Phio Pharmaceuticals Corp. sustain its profitability2025 Momentum Check & Long-Term Growth Portfolio Plans - mfd.ru
Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference - TMX Newsfile
Cancer drug developer Phio joins free Atlantic City investor discovery event - stocktitan.net
Aug PreEarnings: Is Hennessy Capital Investment Corp VII stock a top performer YTDJuly 2025 Macro Moves & Consistent Return Investment Signals - baoquankhu1.vn
Phio Pharmaceuticals reports 70% response rate in skin cancer trial By Investing.com - Investing.com India
Phio Reports Positive Phase 1b PH-762 Skin Cancer Data - TipRanks
Phio Pharmaceuticals Corp Announces Key Tumor Response Data from PH-762 Trial - TradingView
Phio Pharmaceuticals reports 70% response rate in skin cancer trial - Investing.com
Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial - TMX Newsfile
Is Phio Pharmaceuticals Corp. stock a contrarian buyLong-Term Growth Stocks & Low Risk Trading Plans - Bollywood Helpline
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - TMX Newsfile
Retail Trends: Does Phio Pharmaceuticals Corp offer margin of safetyJuly 2025 Review & Community Trade Idea Sharing Platform - baoquankhu1.vn
Finanzdaten der Phio Pharmaceuticals Corp-Aktie (PHIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Phio Pharmaceuticals Corp-Aktie (PHIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bitterman Robert J | Chairman, Pres. & CEO |
Dec 23 '25 |
Buy |
1.02 |
5,000 |
5,100 |
286,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 21 '25 |
Buy |
1.14 |
5,000 |
5,700 |
281,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 18 '25 |
Buy |
1.27 |
5,000 |
6,350 |
276,421 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 10 '25 |
Buy |
2.42 |
2,000 |
4,840 |
27,149 |
| Ferrara Robert L | Director |
Jun 10 '25 |
Buy |
2.42 |
2,500 |
6,050 |
15,666 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 09 '25 |
Buy |
2.75 |
1,500 |
4,125 |
25,149 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 21 '25 |
Buy |
1.77 |
3,000 |
5,310 |
22,449 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 22 '25 |
Buy |
1.78 |
1,200 |
2,136 |
23,649 |
| Ferrara Robert L | Director |
May 20 '25 |
Buy |
1.82 |
2,500 |
4,550 |
13,166 |
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):